Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use

JW. van Straalen, RM. Krol, G. Giancane, V. Panaviene, LM. Ailioaie, P. Doležalová, M. Cattalini, G. Susic, FR. Sztajnbok, D. Maritsi, T. Constantin, S. Sawhney, M. Rygg, SK. Oliveira, EB. Nordal, C. Saad-Magalhães, N. Rubio-Perez, M. Jelusic, S....

. 2022 ; 61 (5) : 2104-2112. [pub] 20220505

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018466

OBJECTIVE: To describe risk factors for IBD development in a cohort of children with JIA. METHODS: JIA patients who developed IBD were identified from the international Pharmachild register. Characteristics were compared between IBD and non-IBD patients and predictors of IBD were determined using multivariable logistic regression analysis. Incidence rates of IBD events on different DMARDs were calculated, and differences between therapies were expressed as relative risks (RR). RESULTS: Out of 8942 patients, 48 (0.54% ) developed IBD. These were more often male (47.9% vs 32.0%) and HLA-B27 positive (38.2% vs 21.0%) and older at JIA onset (median 8.94 vs 5.33 years) than patients without IBD development. They also had more often a family history of autoimmune disease (42.6% vs 24.4%) and enthesitis-related arthritis (39.6% vs 10.8%). The strongest predictors of IBD on multivariable analysis were enthesitis-related arthritis [odds ratio (OR): 3.68, 95% CI: 1.41, 9.40] and a family history of autoimmune disease (OR: 2.27, 95% CI: 1.12, 4.54). Compared with methotrexate monotherapy, the incidence of IBD on etanercept monotherapy (RR: 7.69, 95% CI: 1.99, 29.74), etanercept with methotrexate (RR: 5.70, 95% CI: 1.42, 22.77) and infliximab (RR: 7.61, 95% CI: 1.27, 45.57) therapy was significantly higher. Incidence on adalimumab was not significantly different (RR: 1.45, 95% CI: 0.15, 13.89). CONCLUSION: IBD in JIA was associated with enthesitis-related arthritis and a family history of autoimmune disease. An increased IBD incidence was observed for etanercept therapy regardless of concomitant methotrexate use.

2nd Department of Pediatrics Athens Medical School National and Kapodistrian University of Athens Athens Greece

Children's Hospital Affiliate of Vilnius University Hospital Santaros Clinic

Clinic of Children's Diseases Vilnius University Vilnius Lithuania

Clinica Pediatrica e Reumatologia IRCCS Istituto Giannina Gaslini

Departamento de Pediatria Facultad de Medicina Hospital Universitario Dr J E González Universidad Autónoma de Nuevo León Monterrey NL Mexico

Department of Clinical and Molecular Medicine Faculty of Medicine and Health Sciences NTNU Norwegian University of Science and Technology

Department of Clinical Medicine UiT the Arctic University of Norway Tromso Norway

Department of Medical Physics Alexandru Ioan Cuza University of Iasi Iasi Romania

Department of Paediatrics University of Zagreb School of Medicine Zagreb Croatia

Department of Pediatric Immunology and Rheumatology Wilhelmina Children's Hospital Utrecht The Netherlands

Department of Pediatrics and Inherited Metabolic Disorders 1st Faculty of Medicine and General University Hospital Charles University Prague Prague Czech Republic

Department of Pediatrics St Olavs University Hospital of Trondheim Trondheim Norway

Department of Pediatrics University Hospital of North Norway

Dipartimento di Neuroscienze Riabilitazione Oftalmologia Genetica e Scienze Materno Infantili Università degli Studi di Genova Genoa Italy

Division of Pediatric Rheumatology Institute of Rheumatology of Belgrade Belgrade Serbia

Instituto de Puericultura e Pediatria Martagao Gesteira Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil

Pediatric Rheumatology Unit São Paulo State University Botucatu Brasil

Sir Ganga Ram Hospital Marg Centre for Child Health Sir Ganga Ram Hospital New Delhi India

Unit of Pediatric Rheumatology Immunology 2nd Department of Pediatrics Semmelweis University Budapest Hungary

Unit of Rheumatology Adolescent Health Studies Center Rio de Janeiro State University Rio de Janeiro Brazil

Unita' di Immunologia e Reumatologia Pediatrica Clinica Pediatrica dell'Universita' di Brescia Spedali Civili Brescia Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018466
003      
CZ-PrNML
005      
20220804134802.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/rheumatology/keab678 $2 doi
035    __
$a (PubMed)34508559
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a van Straalen, Joeri W $u Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, Utrecht, The Netherlands
245    10
$a Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use / $c JW. van Straalen, RM. Krol, G. Giancane, V. Panaviene, LM. Ailioaie, P. Doležalová, M. Cattalini, G. Susic, FR. Sztajnbok, D. Maritsi, T. Constantin, S. Sawhney, M. Rygg, SK. Oliveira, EB. Nordal, C. Saad-Magalhães, N. Rubio-Perez, M. Jelusic, S. de Roock, NM. Wulffraat, N. Ruperto, JF. Swart
520    9_
$a OBJECTIVE: To describe risk factors for IBD development in a cohort of children with JIA. METHODS: JIA patients who developed IBD were identified from the international Pharmachild register. Characteristics were compared between IBD and non-IBD patients and predictors of IBD were determined using multivariable logistic regression analysis. Incidence rates of IBD events on different DMARDs were calculated, and differences between therapies were expressed as relative risks (RR). RESULTS: Out of 8942 patients, 48 (0.54% ) developed IBD. These were more often male (47.9% vs 32.0%) and HLA-B27 positive (38.2% vs 21.0%) and older at JIA onset (median 8.94 vs 5.33 years) than patients without IBD development. They also had more often a family history of autoimmune disease (42.6% vs 24.4%) and enthesitis-related arthritis (39.6% vs 10.8%). The strongest predictors of IBD on multivariable analysis were enthesitis-related arthritis [odds ratio (OR): 3.68, 95% CI: 1.41, 9.40] and a family history of autoimmune disease (OR: 2.27, 95% CI: 1.12, 4.54). Compared with methotrexate monotherapy, the incidence of IBD on etanercept monotherapy (RR: 7.69, 95% CI: 1.99, 29.74), etanercept with methotrexate (RR: 5.70, 95% CI: 1.42, 22.77) and infliximab (RR: 7.61, 95% CI: 1.27, 45.57) therapy was significantly higher. Incidence on adalimumab was not significantly different (RR: 1.45, 95% CI: 0.15, 13.89). CONCLUSION: IBD in JIA was associated with enthesitis-related arthritis and a family history of autoimmune disease. An increased IBD incidence was observed for etanercept therapy regardless of concomitant methotrexate use.
650    12
$a antirevmatika $x škodlivé účinky $7 D018501
650    12
$a juvenilní artritida $x farmakoterapie $x epidemiologie $7 D001171
650    _2
$a dítě $7 D002648
650    _2
$a etanercept $x škodlivé účinky $7 D000068800
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    12
$a idiopatické střevní záněty $x farmakoterapie $x epidemiologie $7 D015212
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methotrexát $x terapeutické užití $7 D008727
650    _2
$a registrace $7 D012042
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Krol, Roline M $u Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, Utrecht, The Netherlands
700    1_
$a Giancane, Gabriella $u Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini $u Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Università degli Studi di Genova, Genoa, Italy
700    1_
$a Panaviene, Violeta $u Children's Hospital, Affiliate of Vilnius University Hospital Santaros Clinic $u Clinic of Children's Diseases, Vilnius University, Vilnius, Lithuania
700    1_
$a Ailioaie, Laura Marinela $u Department of Medical Physics, Alexandru Ioan Cuza University of Iasi, Iasi, Romania
700    1_
$a Doležalová, Pavla $u Department of Pediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic
700    1_
$a Cattalini, Marco $u Unita' di Immunologia e Reumatologia Pediatrica, Clinica Pediatrica dell'Universita' di Brescia, Spedali Civili, Brescia, Italy
700    1_
$a Susic, Gordana $u Division of Pediatric Rheumatology, Institute of Rheumatology of Belgrade, Belgrade, Serbia
700    1_
$a Sztajnbok, Flavio R $u Unit of Rheumatology, Adolescent Health Studies Center (NESA), Rio de Janeiro State University, Rio de Janeiro, Brazil
700    1_
$a Maritsi, Despoina $u 2nd Department of Pediatrics Athens Medical School, National and Kapodistrian University of Athens (NKUA), Athens, Greece
700    1_
$a Constantin, Tamas $u Unit of Pediatric Rheumatology-Immunology, Second Department of Pediatrics, Semmelweis University, Budapest, Hungary
700    1_
$a Sawhney, Sujata $u Sir Ganga Ram Hospital Marg, Centre for Child Health, Sir Ganga Ram Hospital, New Delhi, India
700    1_
$a Rygg, Marite $u Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU-Norwegian University of Science and Technology $u Department of Pediatrics, St Olavs University Hospital of Trondheim, Trondheim, Norway
700    1_
$a Oliveira, Sheila Knupp $u Instituto de Puericultura e Pediatria Martagao Gesteira (IPPMG), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
700    1_
$a Nordal, Ellen Berit $u Department of Pediatrics, University Hospital of North Norway $u Department of Clinical Medicine, UiT the Arctic University of Norway, Tromso, Norway
700    1_
$a Saad-Magalhães, Claudia $u Pediatric Rheumatology Unit, São Paulo State University (UNESP), Botucatu, Brasil
700    1_
$a Rubio-Perez, Nadina $u Departamento de Pediatria, Facultad de Medicina, Hospital Universitario "Dr. J. E. González", Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico
700    1_
$a Jelusic, Marija $u Department of Paediatrics, University of Zagreb School of Medicine, Zagreb, Croatia
700    1_
$a de Roock, Sytze $u Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, Utrecht, The Netherlands
700    1_
$a Wulffraat, Nico M $u Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, Utrecht, The Netherlands
700    1_
$a Ruperto, Nicolino $u Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini $1 https://orcid.org/0000000184077782
700    1_
$a Swart, Joost F $u Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, Utrecht, The Netherlands $1 https://orcid.org/0000000227592822
773    0_
$w MED00011379 $t Rheumatology (Oxford, England) $x 1462-0332 $g Roč. 61, č. 5 (2022), s. 2104-2112
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34508559 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134755 $b ABA008
999    __
$a ok $b bmc $g 1822175 $s 1169709
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 61 $c 5 $d 2104-2112 $e 20220505 $i 1462-0332 $m Rheumatology $n Rheumatology (Oxford) $x MED00011379
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...